Tilmann Buerckstuemmer, PhD

CSO
Myllia Biotechnology

Panelist

Tilmann Buerckstuemmer, PhD

Tilmann Buerckstuemmer, PhD, is a CRISPR enthusiast since the early days of CRISPR. Originally trained as a biochemist, he joined Haplogen as principal scientist and later became their CSO. Following the acquisition by Horizon Discovery, Tilmann served as director of research and development and later as head of innovation, where he oversaw the company’s technology platform and innovation agenda. In 2018, he co-founded Myllia Biotechnology which focuses on single-cell CRISPR screens. He is also the CEO of bit.bio discovery, a joined venture between Vienna-based Myllia Biotechnology and Cambridge-based bit.bio. Tilmann is passionate about science and enjoys working with multi-disciplinary and multi-national teams.

Jens Durruthy, PhD

Director of Product Management
Element Biosciences

Panelist

Jens Durruthy, PhD

Jens Durruthy Durruthy, PhD, is the director of product management at Element Biosciences. Prior experience includes a decade at 10x Genomics, where he developed and oversaw the product portfolio for Chromium products. Jens held the position of LSA Bio/Genomics Fellow at Life Science Angels, conducting extensive research on investment opportunities in biotech and genomics startups, and has worked in various consulting roles, focusing on product development and market analysis. Educational credentials include a PhD in biomedical engineering from Stanford University and a diploma in medical biotechnology from Technische Universität Berlin.

Broadcast Date: 
  • Time: 

Integrated pooled CRISPR screening linked to imaging readouts accelerate target identification and functional characterization of signaling pathways. A good example of this can be found in studies of NF-κB signaling, which is central to inflammatory responses and driven by rapid nuclear translocation of the p50/p65 complex to activate transcriptional programs following cytokine stimulation.

In this GEN webinar, Tilmann Buerckstuemmer, PhD, CSO at Myllia Biotechnology will show how high-throughput pooled CRISPR screening combined with cell painting readouts characterized important signaling pathways using NF-κB nuclear translocation as a case study. During the webinar, you will learn how the AVITI24

Key takeaways include:

  • Strategies for linking CRISPR perturbations to protein localization and morphological features at single-cell resolution

  • Identification of hitherto poorly characterized chromatin modifying complexes in regulating NF-κB signaling

  • The value of multimodal readouts, including morphology, in adding depth and confidence to recovered biology

  • How this approach supports mechanism-of-action studies and enables identification of both positive and negative regulators of signaling pathways

    • A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.

    Produced with support from:

    The post Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells appeared first on GEN - Genetic Engineering and Biotechnology News.